Patent · US Active

T7 RNA polymerase variants with cysteine-serine substitutions

US9663769B2 · kind B2 · utility

1Cited by

1References

5Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Michael Greif · Penzberg, DE
Christian Rudolph · Penzberg, DE
Manfred Schmidt · Krefeld, DE
Harald Sobek · Penzberg, DE
Johann-Peter Thalhofer · Weilheim, DE

Key dates

Filing date	Oct 1, 2015
Grant date	May 30, 2017
Priority date	—
Expiry date	Oct 1, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y207/07006
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present disclosure provide novel variants of T7 RNA polymerase. Embodiments of T7 variants, according to the instant invention, include a Cysteine-Serine substitution on position 723 of the amino acid sequence of the T7 polypeptide. Embodiments of T7 variants according to the instant invention have a DNA-dependent RNA polymerase enzymatic activity and a reduced tendency to form intramolecular homodimers by way of oxidizing thiol groups. The amino acid substitutions within the T7 variants disclosed herein impact minimally, if at all, the RNA polymerase activity of the T7 polypeptide. Further, the mutations of the disclosed embodiments may optionally be combined with mutations which provide enhanced thermostability compared to the wild-type reference.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.